 Gene H. Kim
Concepts (700)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 61 | 2021 | 617 | 7.240 |
Why?
| | Heart Failure | 65 | 2021 | 1027 | 6.400 |
Why?
| | Ventricular Function, Left | 21 | 2020 | 555 | 2.420 |
Why?
| | Hemodynamics | 23 | 2020 | 700 | 2.370 |
Why?
| | Heart Ventricles | 19 | 2021 | 765 | 2.210 |
Why?
| | MicroRNAs | 7 | 2017 | 494 | 2.210 |
Why?
| | Heart Transplantation | 12 | 2021 | 641 | 1.740 |
Why?
| | Arrhythmias, Cardiac | 5 | 2017 | 196 | 1.630 |
Why?
| | Pulmonary Wedge Pressure | 12 | 2021 | 108 | 1.460 |
Why?
| | Middle Aged | 90 | 2021 | 25178 | 1.270 |
Why?
| | Aortic Valve Insufficiency | 7 | 2020 | 113 | 1.240 |
Why?
| | Humans | 143 | 2021 | 80482 | 1.210 |
Why?
| | Myocardium | 6 | 2017 | 536 | 1.200 |
Why?
| | Male | 105 | 2021 | 41036 | 1.130 |
Why?
| | Prosthesis Implantation | 7 | 2020 | 127 | 1.130 |
Why?
| | Cardiomyopathies | 6 | 2020 | 239 | 1.120 |
Why?
| | Female | 100 | 2021 | 43684 | 1.110 |
Why?
| | Skin Neoplasms | 6 | 2020 | 535 | 1.070 |
Why?
| | Cornea | 2 | 2014 | 97 | 1.050 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 84 | 1.020 |
Why?
| | Epigenesis, Genetic | 3 | 2017 | 412 | 0.990 |
Why?
| | Myocytes, Cardiac | 6 | 2016 | 240 | 0.980 |
Why?
| | Echocardiography | 16 | 2020 | 852 | 0.930 |
Why?
| | Skin | 6 | 2020 | 552 | 0.920 |
Why?
| | S100 Proteins | 5 | 2013 | 53 | 0.920 |
Why?
| | Gene Expression Regulation | 9 | 2017 | 1918 | 0.870 |
Why?
| | Folliculitis | 1 | 2020 | 2 | 0.870 |
Why?
| | Mesotherapy | 1 | 2020 | 2 | 0.870 |
Why?
| | Foot Diseases | 1 | 2019 | 13 | 0.850 |
Why?
| | Echocardiography, Doppler | 8 | 2020 | 197 | 0.840 |
Why?
| | Foot | 1 | 2019 | 55 | 0.830 |
Why?
| | Hemangioma | 1 | 2019 | 64 | 0.830 |
Why?
| | Gap Junctions | 2 | 2017 | 141 | 0.790 |
Why?
| | Signal Transduction | 9 | 2020 | 3274 | 0.770 |
Why?
| | Aged | 55 | 2021 | 18161 | 0.770 |
Why?
| | Cardiology | 1 | 2019 | 110 | 0.740 |
Why?
| | Cosmetic Techniques | 2 | 2015 | 35 | 0.740 |
Why?
| | Retrospective Studies | 33 | 2020 | 7284 | 0.730 |
Why?
| | Treatment Outcome | 34 | 2021 | 7692 | 0.720 |
Why?
| | Desmosomes | 1 | 2017 | 9 | 0.720 |
Why?
| | Disease Models, Animal | 9 | 2019 | 2248 | 0.710 |
Why?
| | Melanoma | 4 | 2020 | 494 | 0.710 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 1 | 2017 | 13 | 0.710 |
Why?
| | Biopsy | 5 | 2019 | 1165 | 0.700 |
Why?
| | Heart Atria | 2 | 2019 | 238 | 0.680 |
Why?
| | Leg Dermatoses | 1 | 2016 | 7 | 0.670 |
Why?
| | Adult | 44 | 2021 | 25396 | 0.670 |
Why?
| | Cryptococcosis | 1 | 2016 | 21 | 0.670 |
Why?
| | Intra-Aortic Balloon Pumping | 4 | 2020 | 66 | 0.670 |
Why?
| | Cellulitis | 1 | 2016 | 22 | 0.670 |
Why?
| | Fungemia | 1 | 2016 | 24 | 0.660 |
Why?
| | Cardiovascular Diseases | 2 | 2014 | 778 | 0.660 |
Why?
| | Immunocompromised Host | 2 | 2020 | 142 | 0.660 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2016 | 33 | 0.660 |
Why?
| | Methanobrevibacter | 2 | 2013 | 3 | 0.640 |
Why?
| | Regeneration | 1 | 2017 | 152 | 0.640 |
Why?
| | Prospective Studies | 25 | 2021 | 3903 | 0.640 |
Why?
| | Hemorrhage | 4 | 2018 | 238 | 0.640 |
Why?
| | Acupuncture Therapy | 1 | 2015 | 10 | 0.620 |
Why?
| | Thrombosis | 5 | 2020 | 268 | 0.610 |
Why?
| | Medical Oncology | 1 | 2019 | 321 | 0.610 |
Why?
| | Sclerosis | 1 | 2015 | 29 | 0.610 |
Why?
| | Leg Ulcer | 1 | 2014 | 8 | 0.610 |
Why?
| | Cell Nucleus | 2 | 2017 | 582 | 0.600 |
Why?
| | Granuloma | 1 | 2015 | 52 | 0.600 |
Why?
| | Irritable Bowel Syndrome | 2 | 2012 | 38 | 0.600 |
Why?
| | Tetracaine | 1 | 2014 | 1 | 0.600 |
Why?
| | Eye Pain | 1 | 2014 | 5 | 0.600 |
Why?
| | Amnion | 1 | 2014 | 14 | 0.600 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2014 | 19 | 0.600 |
Why?
| | Coated Materials, Biocompatible | 1 | 2014 | 31 | 0.600 |
Why?
| | Embolism | 1 | 2014 | 31 | 0.590 |
Why?
| | Heart Conduction System | 2 | 2012 | 146 | 0.590 |
Why?
| | Conjunctiva | 1 | 2014 | 25 | 0.590 |
Why?
| | Immunosuppressive Agents | 3 | 2020 | 1019 | 0.590 |
Why?
| | Eye Injuries | 1 | 2014 | 15 | 0.590 |
Why?
| | Prostheses and Implants | 2 | 2018 | 143 | 0.580 |
Why?
| | Lasers, Excimer | 1 | 2014 | 6 | 0.580 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2014 | 4 | 0.570 |
Why?
| | Animals | 38 | 2020 | 26575 | 0.570 |
Why?
| | Photorefractive Keratectomy | 1 | 2014 | 6 | 0.570 |
Why?
| | Myopia | 1 | 2014 | 12 | 0.570 |
Why?
| | Face | 1 | 2015 | 126 | 0.570 |
Why?
| | Membrane Glycoproteins | 1 | 2017 | 428 | 0.560 |
Why?
| | Foreign Bodies | 1 | 2014 | 63 | 0.560 |
Why?
| | Trigeminal Nerve | 1 | 2013 | 18 | 0.560 |
Why?
| | Cardiomegaly | 6 | 2016 | 109 | 0.560 |
Why?
| | Anesthetics, Local | 1 | 2014 | 80 | 0.560 |
Why?
| | Prednisone | 3 | 2020 | 261 | 0.560 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 126 | 0.560 |
Why?
| | Suture Techniques | 1 | 2014 | 139 | 0.550 |
Why?
| | Connexin 43 | 1 | 2014 | 93 | 0.540 |
Why?
| | Immunoglobulin G | 3 | 2020 | 469 | 0.540 |
Why?
| | Thromboembolism | 3 | 2018 | 119 | 0.540 |
Why?
| | Nerve Fibers | 1 | 2013 | 43 | 0.540 |
Why?
| | Panniculitis | 1 | 2013 | 7 | 0.540 |
Why?
| | Lactoglobulins | 1 | 2012 | 7 | 0.530 |
Why?
| | Device Removal | 3 | 2020 | 153 | 0.530 |
Why?
| | Fox-Fordyce Disease | 1 | 2012 | 2 | 0.530 |
Why?
| | Xanthomatosis | 1 | 2012 | 10 | 0.530 |
Why?
| | Hypertrichosis | 1 | 2012 | 4 | 0.520 |
Why?
| | Neurocytoma | 1 | 2012 | 3 | 0.520 |
Why?
| | Cardiac Output | 5 | 2020 | 154 | 0.520 |
Why?
| | Facial Neoplasms | 1 | 2012 | 27 | 0.510 |
Why?
| | Heart | 4 | 2019 | 514 | 0.510 |
Why?
| | Methane | 1 | 2012 | 11 | 0.500 |
Why?
| | Follow-Up Studies | 15 | 2021 | 3811 | 0.500 |
Why?
| | Mice | 24 | 2020 | 10937 | 0.490 |
Why?
| | Oxidation-Reduction | 1 | 2013 | 375 | 0.490 |
Why?
| | Constipation | 1 | 2012 | 65 | 0.480 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 2011 | 3 | 0.470 |
Why?
| | Facial Dermatoses | 1 | 2011 | 12 | 0.470 |
Why?
| | Mice, Transgenic | 13 | 2019 | 1532 | 0.470 |
Why?
| | Ultrasonography, Prenatal | 1 | 2013 | 175 | 0.470 |
Why?
| | Postoperative Complications | 9 | 2020 | 2242 | 0.450 |
Why?
| | Indoles | 1 | 2013 | 327 | 0.450 |
Why?
| | Hypertension, Pulmonary | 4 | 2020 | 328 | 0.440 |
Why?
| | Sulfonamides | 1 | 2013 | 308 | 0.440 |
Why?
| | Sirtuin 3 | 4 | 2016 | 30 | 0.440 |
Why?
| | Atrial Fibrillation | 4 | 2019 | 248 | 0.440 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1584 | 0.430 |
Why?
| | Histiocytosis, Sinus | 2 | 2020 | 16 | 0.420 |
Why?
| | Lymphedema | 3 | 2020 | 74 | 0.420 |
Why?
| | Recovery of Function | 4 | 2019 | 259 | 0.410 |
Why?
| | Kidney Transplantation | 3 | 2021 | 818 | 0.410 |
Why?
| | Aortic Valve | 4 | 2020 | 185 | 0.410 |
Why?
| | Echocardiography, Three-Dimensional | 4 | 2021 | 495 | 0.400 |
Why?
| | Tricuspid Valve | 2 | 2020 | 80 | 0.400 |
Why?
| | Methotrexate | 2 | 2020 | 256 | 0.400 |
Why?
| | Liver Transplantation | 4 | 2021 | 1229 | 0.390 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 341 | 0.390 |
Why?
| | Pulmonary Artery | 3 | 2021 | 293 | 0.390 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2009 | 92 | 0.390 |
Why?
| | Anti-Bacterial Agents | 3 | 2020 | 776 | 0.390 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 102 | 0.390 |
Why?
| | Tricuspid Valve Insufficiency | 2 | 2020 | 91 | 0.380 |
Why?
| | Counterpulsation | 2 | 2018 | 21 | 0.380 |
Why?
| | Heart Valve Prosthesis Implantation | 2 | 2020 | 140 | 0.370 |
Why?
| | Cardiotonic Agents | 3 | 2019 | 82 | 0.370 |
Why?
| | Pacemaker, Artificial | 2 | 2020 | 96 | 0.370 |
Why?
| | Coronary Artery Bypass | 3 | 2020 | 196 | 0.370 |
Why?
| | Lymph Node Excision | 2 | 2019 | 214 | 0.360 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2020 | 212 | 0.360 |
Why?
| | Radiotherapy | 2 | 2019 | 341 | 0.350 |
Why?
| | Lichen Planus | 1 | 2007 | 7 | 0.350 |
Why?
| | Photosensitivity Disorders | 1 | 2007 | 15 | 0.350 |
Why?
| | Protein Biosynthesis | 1 | 2009 | 375 | 0.340 |
Why?
| | Muscle, Smooth, Vascular | 4 | 2013 | 247 | 0.330 |
Why?
| | Energy Metabolism | 2 | 2019 | 260 | 0.330 |
Why?
| | Graft Rejection | 4 | 2021 | 1101 | 0.330 |
Why?
| | Psoriasis | 1 | 2009 | 213 | 0.330 |
Why?
| | Leiomyomatosis | 1 | 2005 | 13 | 0.320 |
Why?
| | Wound Healing | 2 | 2020 | 347 | 0.320 |
Why?
| | Transcription Factors | 2 | 2014 | 1488 | 0.310 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 132 | 0.310 |
Why?
| | Nails, Malformed | 1 | 2004 | 4 | 0.300 |
Why?
| | Urticaria | 1 | 2004 | 11 | 0.300 |
Why?
| | Oxidative Stress | 4 | 2019 | 403 | 0.300 |
Why?
| | Time Factors | 12 | 2021 | 5437 | 0.300 |
Why?
| | Hair | 1 | 2004 | 53 | 0.290 |
Why?
| | Mitochondria | 3 | 2019 | 520 | 0.290 |
Why?
| | Craniofacial Abnormalities | 1 | 2004 | 37 | 0.290 |
Why?
| | Cold Temperature | 1 | 2004 | 160 | 0.290 |
Why?
| | Patient Readmission | 4 | 2020 | 278 | 0.280 |
Why?
| | DNA-Binding Proteins | 2 | 2012 | 1185 | 0.270 |
Why?
| | Osteopoikilosis | 1 | 2003 | 1 | 0.270 |
Why?
| | Skin Diseases, Genetic | 1 | 2003 | 2 | 0.270 |
Why?
| | Sirtuins | 3 | 2016 | 45 | 0.270 |
Why?
| | Central Venous Pressure | 2 | 2020 | 27 | 0.260 |
Why?
| | Visual Acuity | 2 | 2014 | 220 | 0.260 |
Why?
| | Uterine Neoplasms | 1 | 2005 | 171 | 0.260 |
Why?
| | Anticoagulants | 4 | 2019 | 372 | 0.260 |
Why?
| | Abnormalities, Multiple | 1 | 2004 | 246 | 0.250 |
Why?
| | T-Lymphocytes | 1 | 2009 | 1275 | 0.240 |
Why?
| | 3' Untranslated Regions | 2 | 2014 | 88 | 0.240 |
Why?
| | NIH 3T3 Cells | 2 | 2014 | 104 | 0.240 |
Why?
| | Survival Rate | 7 | 2021 | 1933 | 0.240 |
Why?
| | Proportional Hazards Models | 6 | 2020 | 868 | 0.240 |
Why?
| | Aortic Aneurysm | 2 | 2014 | 77 | 0.240 |
Why?
| | Blood Flow Velocity | 2 | 2019 | 202 | 0.240 |
Why?
| | Stroke Volume | 3 | 2019 | 405 | 0.240 |
Why?
| | Bone and Bones | 1 | 2003 | 264 | 0.230 |
Why?
| | Kidney Failure, Chronic | 2 | 2020 | 511 | 0.230 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2020 | 11 | 0.230 |
Why?
| | Glomus Tumor | 1 | 2020 | 6 | 0.230 |
Why?
| | Penicillin G Benzathine | 1 | 2020 | 5 | 0.220 |
Why?
| | Atherosclerosis | 2 | 2014 | 224 | 0.220 |
Why?
| | Cohort Studies | 9 | 2020 | 2626 | 0.220 |
Why?
| | Risk Factors | 8 | 2020 | 5279 | 0.220 |
Why?
| | Sulfadiazine | 1 | 2020 | 25 | 0.220 |
Why?
| | Apolipoproteins E | 2 | 2013 | 146 | 0.220 |
Why?
| | Trimethoprim | 1 | 2020 | 13 | 0.220 |
Why?
| | Treponema pallidum | 1 | 2020 | 9 | 0.220 |
Why?
| | Agammaglobulinemia | 1 | 2020 | 21 | 0.220 |
Why?
| | Epidermolysis Bullosa, Junctional | 1 | 2020 | 1 | 0.220 |
Why?
| | Ambulatory Care | 2 | 2018 | 176 | 0.220 |
Why?
| | Gentamicins | 1 | 2020 | 49 | 0.220 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 29 | 0.220 |
Why?
| | Poroma | 1 | 2019 | 1 | 0.210 |
Why?
| | HIV Seropositivity | 1 | 2020 | 71 | 0.210 |
Why?
| | Syphilis | 1 | 2020 | 25 | 0.210 |
Why?
| | Cause of Death | 2 | 2018 | 273 | 0.210 |
Why?
| | Codon, Nonsense | 1 | 2020 | 41 | 0.210 |
Why?
| | Mathematical Concepts | 1 | 2020 | 16 | 0.210 |
Why?
| | Sweat Gland Neoplasms | 1 | 2019 | 8 | 0.210 |
Why?
| | Fontan Procedure | 1 | 2020 | 50 | 0.210 |
Why?
| | Risk Assessment | 5 | 2020 | 2239 | 0.210 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2020 | 78 | 0.210 |
Why?
| | Porokeratosis | 1 | 2019 | 3 | 0.210 |
Why?
| | Electric Impedance | 1 | 2020 | 92 | 0.210 |
Why?
| | Vascular Stiffness | 1 | 2019 | 25 | 0.210 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2020 | 77 | 0.210 |
Why?
| | Protein-Serine-Threonine Kinases | 2 | 2017 | 543 | 0.210 |
Why?
| | Hair Follicle | 1 | 2019 | 25 | 0.210 |
Why?
| | Syndrome | 3 | 2005 | 433 | 0.200 |
Why?
| | Intraoperative Care | 1 | 2020 | 94 | 0.200 |
Why?
| | Cheek | 2 | 2011 | 19 | 0.200 |
Why?
| | Neoplasms, Second Primary | 2 | 2020 | 235 | 0.200 |
Why?
| | Cartilage | 2 | 2018 | 117 | 0.200 |
Why?
| | Protease Inhibitors | 1 | 2019 | 74 | 0.200 |
Why?
| | Sternotomy | 1 | 2019 | 13 | 0.200 |
Why?
| | Severity of Illness Index | 7 | 2020 | 1738 | 0.200 |
Why?
| | Myocarditis | 1 | 2019 | 44 | 0.200 |
Why?
| | Vasodilation | 1 | 2019 | 98 | 0.200 |
Why?
| | Tetrazoles | 1 | 2019 | 54 | 0.200 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 161 | 0.200 |
Why?
| | Multiple Organ Failure | 1 | 2019 | 39 | 0.200 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2020 | 161 | 0.200 |
Why?
| | Calcinosis | 2 | 2011 | 238 | 0.200 |
Why?
| | Remote Sensing Technology | 1 | 2018 | 5 | 0.200 |
Why?
| | Mice, Knockout | 8 | 2019 | 1924 | 0.200 |
Why?
| | Assisted Circulation | 1 | 2018 | 14 | 0.200 |
Why?
| | Lunate Bone | 1 | 2018 | 2 | 0.200 |
Why?
| | Heart Function Tests | 1 | 2018 | 31 | 0.200 |
Why?
| | Shock, Cardiogenic | 1 | 2019 | 71 | 0.200 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 99 | 0.200 |
Why?
| | Guided Tissue Regeneration | 1 | 2018 | 7 | 0.200 |
Why?
| | Trapezium Bone | 1 | 2018 | 6 | 0.200 |
Why?
| | Thyroid Diseases | 1 | 2019 | 114 | 0.190 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 244 | 0.190 |
Why?
| | Donor Selection | 1 | 2019 | 66 | 0.190 |
Why?
| | Atrial Appendage | 1 | 2018 | 20 | 0.190 |
Why?
| | Carpometacarpal Joints | 1 | 2018 | 12 | 0.190 |
Why?
| | Subclavian Artery | 2 | 2015 | 37 | 0.190 |
Why?
| | Arthroplasty | 1 | 2018 | 28 | 0.190 |
Why?
| | Alopecia | 2 | 2019 | 33 | 0.190 |
Why?
| | Autoimmune Diseases | 2 | 2011 | 231 | 0.190 |
Why?
| | Reperfusion Injury | 1 | 2020 | 154 | 0.190 |
Why?
| | Enoxaparin | 1 | 2018 | 23 | 0.190 |
Why?
| | Mice, Inbred C57BL | 9 | 2019 | 3136 | 0.190 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2018 | 66 | 0.190 |
Why?
| | Octreotide | 1 | 2018 | 24 | 0.190 |
Why?
| | Tattooing | 1 | 2017 | 6 | 0.190 |
Why?
| | Erythema Nodosum | 1 | 2017 | 4 | 0.190 |
Why?
| | Predictive Value of Tests | 6 | 2019 | 1682 | 0.190 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2018 | 55 | 0.190 |
Why?
| | Graphite | 1 | 2017 | 9 | 0.180 |
Why?
| | Mitral Valve | 1 | 2020 | 217 | 0.180 |
Why?
| | Nerve Tissue Proteins | 2 | 2013 | 527 | 0.180 |
Why?
| | Equipment Failure | 4 | 2020 | 124 | 0.180 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2018 | 54 | 0.180 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2019 | 69 | 0.180 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 16 | 0.180 |
Why?
| | Nevus, Pigmented | 1 | 2018 | 50 | 0.180 |
Why?
| | Eye Injuries, Penetrating | 1 | 2017 | 9 | 0.180 |
Why?
| | Testosterone | 1 | 2019 | 287 | 0.180 |
Why?
| | Heart Valve Diseases | 1 | 2018 | 98 | 0.180 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2018 | 164 | 0.180 |
Why?
| | Skin Ulcer | 1 | 2017 | 25 | 0.180 |
Why?
| | Illusions | 1 | 2017 | 11 | 0.180 |
Why?
| | Rhinoplasty | 1 | 2018 | 32 | 0.180 |
Why?
| | Thermodilution | 1 | 2017 | 20 | 0.180 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2018 | 109 | 0.180 |
Why?
| | Rats | 8 | 2020 | 4331 | 0.180 |
Why?
| | Tachycardia, Ventricular | 1 | 2020 | 214 | 0.180 |
Why?
| | Surgical Flaps | 1 | 2020 | 261 | 0.170 |
Why?
| | Secondary Prevention | 1 | 2018 | 162 | 0.170 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 1 | 2017 | 28 | 0.170 |
Why?
| | Atrial Flutter | 1 | 2017 | 46 | 0.170 |
Why?
| | Fibronectins | 1 | 2017 | 94 | 0.170 |
Why?
| | Insulin Resistance | 1 | 2019 | 382 | 0.170 |
Why?
| | Catheter Ablation | 1 | 2020 | 331 | 0.170 |
Why?
| | Cryptococcus neoformans | 1 | 2016 | 15 | 0.170 |
Why?
| | Fluconazole | 1 | 2016 | 16 | 0.170 |
Why?
| | Myocardial Ischemia | 2 | 2017 | 165 | 0.170 |
Why?
| | Flucytosine | 1 | 2016 | 13 | 0.170 |
Why?
| | Hydrogen Sulfide | 1 | 2017 | 44 | 0.170 |
Why?
| | Amphotericin B | 1 | 2016 | 46 | 0.170 |
Why?
| | Carbon Monoxide | 1 | 2017 | 92 | 0.170 |
Why?
| | Angiopoietin-2 | 1 | 2016 | 19 | 0.170 |
Why?
| | Prosthesis Design | 4 | 2019 | 297 | 0.160 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 275 | 0.160 |
Why?
| | Coloring Agents | 2 | 2012 | 71 | 0.160 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 135 | 0.160 |
Why?
| | Mitochondria, Heart | 1 | 2016 | 44 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2017 | 160 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2019 | 276 | 0.160 |
Why?
| | Superoxide Dismutase | 3 | 2015 | 185 | 0.160 |
Why?
| | Extracellular Matrix | 1 | 2017 | 223 | 0.160 |
Why?
| | Reproducibility of Results | 4 | 2018 | 2622 | 0.160 |
Why?
| | Lymph Nodes | 1 | 2020 | 524 | 0.160 |
Why?
| | Rats, Inbred SHR | 2 | 2017 | 29 | 0.160 |
Why?
| | Sleep Apnea Syndromes | 1 | 2017 | 122 | 0.150 |
Why?
| | Antifungal Agents | 1 | 2016 | 135 | 0.150 |
Why?
| | Lignans | 1 | 2015 | 6 | 0.150 |
Why?
| | Phenotype | 3 | 2017 | 2241 | 0.150 |
Why?
| | Observer Variation | 2 | 2016 | 619 | 0.150 |
Why?
| | Lasers, Gas | 1 | 2014 | 4 | 0.150 |
Why?
| | Cyclosporine | 1 | 2016 | 248 | 0.150 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 52 | 0.150 |
Why?
| | DNA, Mitochondrial | 1 | 2016 | 181 | 0.150 |
Why?
| | Doxorubicin | 1 | 2016 | 293 | 0.150 |
Why?
| | LIM Domain Proteins | 1 | 2014 | 22 | 0.150 |
Why?
| | Incidence | 5 | 2019 | 1587 | 0.150 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2014 | 15 | 0.150 |
Why?
| | Cephalosporins | 1 | 2014 | 43 | 0.150 |
Why?
| | Mesenteric Artery, Superior | 1 | 2014 | 22 | 0.150 |
Why?
| | Mitral Valve Insufficiency | 1 | 2016 | 165 | 0.150 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1637 | 0.150 |
Why?
| | Coronavirus Infections | 1 | 2020 | 283 | 0.150 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 309 | 0.150 |
Why?
| | Toxoplasmosis | 1 | 2015 | 63 | 0.140 |
Why?
| | Melkersson-Rosenthal Syndrome | 1 | 2014 | 1 | 0.140 |
Why?
| | Refraction, Ocular | 1 | 2014 | 11 | 0.140 |
Why?
| | Posture | 1 | 2014 | 108 | 0.140 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 413 | 0.140 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2014 | 11 | 0.140 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 2069 | 0.140 |
Why?
| | Nails | 1 | 2014 | 8 | 0.140 |
Why?
| | Eyelid Diseases | 1 | 2014 | 9 | 0.140 |
Why?
| | Infant | 3 | 2021 | 3026 | 0.140 |
Why?
| | Transduction, Genetic | 1 | 2014 | 153 | 0.140 |
Why?
| | Luciferases | 1 | 2014 | 122 | 0.140 |
Why?
| | Transforming Growth Factor beta | 2 | 2013 | 283 | 0.140 |
Why?
| | Connective Tissue Diseases | 1 | 2014 | 66 | 0.140 |
Why?
| | Exosomes | 1 | 2014 | 48 | 0.140 |
Why?
| | Myosin Heavy Chains | 1 | 2014 | 87 | 0.140 |
Why?
| | Catheterization, Peripheral | 1 | 2014 | 63 | 0.140 |
Why?
| | Arterial Occlusive Diseases | 1 | 2014 | 99 | 0.140 |
Why?
| | Hospitalization | 1 | 2019 | 741 | 0.140 |
Why?
| | Mutation, Missense | 2 | 2013 | 274 | 0.140 |
Why?
| | Patient Positioning | 1 | 2014 | 65 | 0.140 |
Why?
| | Vasculitis | 2 | 2013 | 40 | 0.140 |
Why?
| | DNA Damage | 1 | 2016 | 349 | 0.140 |
Why?
| | Edema | 1 | 2014 | 74 | 0.140 |
Why?
| | Frozen Sections | 1 | 2014 | 48 | 0.140 |
Why?
| | Genetic Testing | 1 | 2018 | 490 | 0.140 |
Why?
| | Gastrointestinal Agents | 2 | 2018 | 172 | 0.140 |
Why?
| | Neovascularization, Pathologic | 1 | 2016 | 352 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2014 | 267 | 0.140 |
Why?
| | Neoplasm Metastasis | 2 | 2020 | 1037 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2020 | 2949 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 1031 | 0.130 |
Why?
| | Carmine | 1 | 2012 | 1 | 0.130 |
Why?
| | Foam Cells | 1 | 2012 | 17 | 0.130 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2012 | 8 | 0.130 |
Why?
| | Oxygen Consumption | 1 | 2014 | 248 | 0.130 |
Why?
| | Prognosis | 5 | 2021 | 3619 | 0.130 |
Why?
| | Pemphigoid, Bullous | 1 | 2012 | 9 | 0.130 |
Why?
| | Illinois | 3 | 2019 | 449 | 0.130 |
Why?
| | Electrocardiography | 4 | 2019 | 570 | 0.130 |
Why?
| | Plaque, Atherosclerotic | 1 | 2013 | 38 | 0.130 |
Why?
| | Oncogene Protein v-akt | 1 | 2012 | 22 | 0.130 |
Why?
| | Mucins | 1 | 2012 | 44 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 2533 | 0.130 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 702 | 0.130 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2012 | 53 | 0.130 |
Why?
| | Reoperation | 3 | 2020 | 619 | 0.130 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 288 | 0.130 |
Why?
| | Genetic Vectors | 1 | 2014 | 448 | 0.130 |
Why?
| | Electrophysiological Phenomena | 1 | 2012 | 50 | 0.130 |
Why?
| | Physicians | 1 | 2019 | 577 | 0.130 |
Why?
| | Lung | 1 | 2018 | 1033 | 0.130 |
Why?
| | Acute Disease | 1 | 2014 | 851 | 0.130 |
Why?
| | Breath Tests | 1 | 2012 | 52 | 0.130 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 297 | 0.130 |
Why?
| | Models, Cardiovascular | 1 | 2012 | 101 | 0.120 |
Why?
| | Axilla | 1 | 2012 | 98 | 0.120 |
Why?
| | Quinolines | 1 | 2013 | 95 | 0.120 |
Why?
| | Hydrogen | 1 | 2012 | 52 | 0.120 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 117 | 0.120 |
Why?
| | Staining and Labeling | 1 | 2012 | 187 | 0.120 |
Why?
| | Weight Gain | 1 | 2013 | 137 | 0.120 |
Why?
| | Collagen Type VII | 1 | 2011 | 3 | 0.120 |
Why?
| | Epidermolysis Bullosa Acquisita | 1 | 2011 | 2 | 0.120 |
Why?
| | Calcium Signaling | 1 | 2012 | 132 | 0.120 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 567 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 133 | 0.120 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 570 | 0.120 |
Why?
| | Cell Communication | 1 | 2012 | 185 | 0.120 |
Why?
| | Feasibility Studies | 3 | 2018 | 715 | 0.120 |
Why?
| | Dermatologic Agents | 1 | 2012 | 68 | 0.120 |
Why?
| | RNA, Bacterial | 1 | 2012 | 109 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 4 | 2020 | 1365 | 0.120 |
Why?
| | Translational Medical Research | 1 | 2012 | 110 | 0.120 |
Why?
| | Rifamycins | 1 | 2011 | 5 | 0.120 |
Why?
| | Amino Acid Substitution | 1 | 2013 | 359 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2016 | 341 | 0.120 |
Why?
| | Sodium Channels | 1 | 2012 | 130 | 0.120 |
Why?
| | Environment | 1 | 2013 | 227 | 0.120 |
Why?
| | T-Box Domain Proteins | 1 | 2012 | 98 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2012 | 246 | 0.110 |
Why?
| | Homeostasis | 1 | 2013 | 392 | 0.110 |
Why?
| | Muscle, Skeletal | 1 | 2014 | 442 | 0.110 |
Why?
| | DNA, Bacterial | 1 | 2012 | 269 | 0.110 |
Why?
| | Disease Progression | 3 | 2020 | 1441 | 0.110 |
Why?
| | Ion Channels | 1 | 2012 | 257 | 0.110 |
Why?
| | Histones | 1 | 2013 | 305 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 3 | 2018 | 903 | 0.110 |
Why?
| | Muscle Contraction | 3 | 2019 | 305 | 0.110 |
Why?
| | Intestine, Small | 1 | 2013 | 340 | 0.110 |
Why?
| | Child | 3 | 2021 | 6516 | 0.110 |
Why?
| | Mitochondria, Muscle | 1 | 2010 | 28 | 0.110 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 2010 | 13 | 0.110 |
Why?
| | Ergocalciferols | 1 | 2010 | 39 | 0.110 |
Why?
| | Fibroblasts | 4 | 2016 | 714 | 0.110 |
Why?
| | Autoimmunity | 1 | 2011 | 161 | 0.110 |
Why?
| | Recurrence | 3 | 2018 | 1165 | 0.110 |
Why?
| | Neural Crest | 1 | 2010 | 24 | 0.110 |
Why?
| | Child, Preschool | 3 | 2020 | 3699 | 0.110 |
Why?
| | NAD | 1 | 2009 | 68 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2011 | 116 | 0.110 |
Why?
| | Feces | 1 | 2012 | 338 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2010 | 73 | 0.100 |
Why?
| | Rare Diseases | 2 | 2020 | 61 | 0.100 |
Why?
| | Lymphatic System | 2 | 2019 | 50 | 0.100 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2009 | 57 | 0.100 |
Why?
| | Drug Combinations | 2 | 2020 | 237 | 0.100 |
Why?
| | Biopsy, Needle | 2 | 2020 | 269 | 0.100 |
Why?
| | Mice, Inbred Strains | 1 | 2009 | 330 | 0.100 |
Why?
| | Immunohistochemistry | 3 | 2020 | 1806 | 0.100 |
Why?
| | Osteogenesis | 1 | 2010 | 238 | 0.100 |
Why?
| | Aged, 80 and over | 4 | 2020 | 6483 | 0.100 |
Why?
| | Forkhead Transcription Factors | 1 | 2009 | 154 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2009 | 115 | 0.090 |
Why?
| | Delayed-Action Preparations | 2 | 2019 | 149 | 0.090 |
Why?
| | DNA Methylation | 1 | 2013 | 564 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2015 | 1596 | 0.090 |
Why?
| | Tissue Donors | 2 | 2021 | 425 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2335 | 0.090 |
Why?
| | Vitamin D | 1 | 2010 | 260 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2015 | 1451 | 0.090 |
Why?
| | Hydroquinones | 1 | 2007 | 9 | 0.090 |
Why?
| | Young Adult | 4 | 2021 | 5784 | 0.090 |
Why?
| | Blood Pressure | 1 | 2013 | 1177 | 0.090 |
Why?
| | Hair Removal | 1 | 2007 | 13 | 0.090 |
Why?
| | Forehead | 1 | 2007 | 18 | 0.090 |
Why?
| | Exercise Test | 2 | 2019 | 167 | 0.090 |
Why?
| | Reactive Oxygen Species | 3 | 2016 | 454 | 0.080 |
Why?
| | United States | 4 | 2021 | 6119 | 0.080 |
Why?
| | Radiation-Protective Agents | 1 | 2007 | 101 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 906 | 0.080 |
Why?
| | Fumarate Hydratase | 1 | 2005 | 6 | 0.080 |
Why?
| | Comorbidity | 2 | 2020 | 894 | 0.080 |
Why?
| | Cell Movement | 1 | 2010 | 736 | 0.080 |
Why?
| | Reference Values | 2 | 2018 | 686 | 0.080 |
Why?
| | Pregnancy | 1 | 2013 | 2709 | 0.080 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 193 | 0.080 |
Why?
| | Alopecia Areata | 1 | 2005 | 4 | 0.080 |
Why?
| | Academic Medical Centers | 2 | 2018 | 386 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2005 | 84 | 0.080 |
Why?
| | Hydrocortisone | 1 | 2007 | 301 | 0.080 |
Why?
| | Survival Analysis | 2 | 2020 | 1586 | 0.070 |
Why?
| | Patient Selection | 2 | 2020 | 687 | 0.070 |
Why?
| | Point Mutation | 1 | 2005 | 266 | 0.070 |
Why?
| | Nuclear Proteins | 1 | 2009 | 683 | 0.070 |
Why?
| | Acetylcholine | 1 | 2004 | 186 | 0.070 |
Why?
| | Ultrasonography | 2 | 2020 | 676 | 0.070 |
Why?
| | Random Allocation | 2 | 2018 | 371 | 0.070 |
Why?
| | Dacryocystorhinostomy | 1 | 2004 | 4 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 1 | 2007 | 338 | 0.070 |
Why?
| | Acetylation | 2 | 2015 | 120 | 0.070 |
Why?
| | Treatment Failure | 2 | 2020 | 306 | 0.070 |
Why?
| | Collagen | 2 | 2019 | 273 | 0.070 |
Why?
| | Elastic Tissue | 2 | 2014 | 17 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2014 | 233 | 0.060 |
Why?
| | Age Factors | 2 | 2018 | 1904 | 0.060 |
Why?
| | Animals, Newborn | 2 | 2014 | 559 | 0.060 |
Why?
| | RNA, Messenger | 3 | 2013 | 1974 | 0.060 |
Why?
| | ABO Blood-Group System | 1 | 2021 | 64 | 0.060 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2021 | 23 | 0.060 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2013 | 131 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 688 | 0.060 |
Why?
| | Pilot Projects | 2 | 2019 | 801 | 0.060 |
Why?
| | Bilirubin | 1 | 2021 | 127 | 0.060 |
Why?
| | Trauma Severity Indices | 1 | 2020 | 39 | 0.060 |
Why?
| | Axillary Artery | 1 | 2020 | 14 | 0.060 |
Why?
| | Aorta | 2 | 2013 | 285 | 0.060 |
Why?
| | Syphilis Serodiagnosis | 1 | 2020 | 4 | 0.060 |
Why?
| | Syphilis, Cutaneous | 1 | 2020 | 4 | 0.060 |
Why?
| | Radiography | 1 | 2003 | 864 | 0.060 |
Why?
| | Immunocompetence | 1 | 2020 | 25 | 0.060 |
Why?
| | Mice, Inbred ICR | 1 | 2020 | 70 | 0.060 |
Why?
| | Thoracic Surgical Procedures | 1 | 2020 | 38 | 0.060 |
Why?
| | California | 1 | 2020 | 134 | 0.060 |
Why?
| | Receptors, Immunologic | 2 | 2013 | 144 | 0.050 |
Why?
| | Exanthema | 1 | 2020 | 29 | 0.050 |
Why?
| | Hyponatremia | 1 | 2020 | 24 | 0.050 |
Why?
| | Administration, Cutaneous | 1 | 2020 | 52 | 0.050 |
Why?
| | Rats, Transgenic | 1 | 2019 | 3 | 0.050 |
Why?
| | Epigastric Arteries | 1 | 2020 | 11 | 0.050 |
Why?
| | Euthyroid Sick Syndromes | 1 | 2019 | 10 | 0.050 |
Why?
| | Reperfusion | 1 | 2020 | 30 | 0.050 |
Why?
| | Succinate Dehydrogenase | 1 | 2019 | 14 | 0.050 |
Why?
| | Sturge-Weber Syndrome | 1 | 2019 | 6 | 0.050 |
Why?
| | Dissection | 1 | 2020 | 47 | 0.050 |
Why?
| | Neprilysin | 1 | 2019 | 40 | 0.050 |
Why?
| | Neurotransmitter Agents | 1 | 2020 | 109 | 0.050 |
Why?
| | Endocrine System Diseases | 1 | 2019 | 30 | 0.050 |
Why?
| | Electron Transport Complex IV | 1 | 2019 | 47 | 0.050 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2019 | 30 | 0.050 |
Why?
| | Femoral Artery | 1 | 2020 | 88 | 0.050 |
Why?
| | Hyperthyroidism | 1 | 2019 | 68 | 0.050 |
Why?
| | Patient Care Planning | 1 | 2020 | 80 | 0.050 |
Why?
| | Materials Testing | 1 | 2019 | 100 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2020 | 306 | 0.050 |
Why?
| | Neck | 1 | 2019 | 83 | 0.050 |
Why?
| | Interdisciplinary Communication | 1 | 2020 | 126 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2021 | 222 | 0.050 |
Why?
| | Hyperplasia | 1 | 2019 | 153 | 0.050 |
Why?
| | Hindlimb | 1 | 2019 | 88 | 0.050 |
Why?
| | Metabolic Diseases | 1 | 2019 | 54 | 0.050 |
Why?
| | Keratinocytes | 1 | 2020 | 132 | 0.050 |
Why?
| | Head | 1 | 2019 | 111 | 0.050 |
Why?
| | Epidermis | 1 | 2019 | 96 | 0.050 |
Why?
| | Heparin | 1 | 2019 | 178 | 0.050 |
Why?
| | Immunosuppression | 1 | 2020 | 351 | 0.050 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 122 | 0.050 |
Why?
| | Systole | 1 | 2019 | 141 | 0.050 |
Why?
| | Thyrotropin | 1 | 2019 | 261 | 0.050 |
Why?
| | Administration, Oral | 1 | 2020 | 709 | 0.050 |
Why?
| | Organ Size | 1 | 2019 | 382 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 1016 | 0.050 |
Why?
| | Thyroxine | 1 | 2019 | 303 | 0.050 |
Why?
| | Hypothyroidism | 1 | 2019 | 196 | 0.050 |
Why?
| | Rats, Nude | 1 | 2018 | 23 | 0.050 |
Why?
| | Injections, Intramuscular | 1 | 2018 | 64 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2019 | 319 | 0.050 |
Why?
| | Ink | 1 | 2017 | 4 | 0.050 |
Why?
| | Coronary Circulation | 1 | 2018 | 132 | 0.050 |
Why?
| | Patient Compliance | 1 | 2020 | 246 | 0.050 |
Why?
| | International Normalized Ratio | 1 | 2018 | 41 | 0.050 |
Why?
| | Fascia | 1 | 2018 | 28 | 0.050 |
Why?
| | Medical History Taking | 1 | 2018 | 82 | 0.050 |
Why?
| | Mutation | 1 | 2009 | 3779 | 0.050 |
Why?
| | Hospitals, University | 1 | 2018 | 201 | 0.050 |
Why?
| | Ischemia | 1 | 2020 | 242 | 0.050 |
Why?
| | Registries | 1 | 2021 | 630 | 0.050 |
Why?
| | Neutropenia | 1 | 2018 | 220 | 0.040 |
Why?
| | Graft Survival | 1 | 2021 | 878 | 0.040 |
Why?
| | Hypoalbuminemia | 1 | 2017 | 6 | 0.040 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2001 | 307 | 0.040 |
Why?
| | Administration, Topical | 1 | 2017 | 98 | 0.040 |
Why?
| | Protein Array Analysis | 1 | 2017 | 51 | 0.040 |
Why?
| | Databases, Factual | 1 | 2021 | 797 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2021 | 951 | 0.040 |
Why?
| | Rats, Inbred WKY | 1 | 2017 | 31 | 0.040 |
Why?
| | Rabbits | 1 | 2018 | 714 | 0.040 |
Why?
| | Tachycardia | 1 | 2017 | 47 | 0.040 |
Why?
| | Cell Survival | 1 | 2020 | 1011 | 0.040 |
Why?
| | Protein Binding | 2 | 2013 | 1487 | 0.040 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2017 | 39 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 978 | 0.040 |
Why?
| | Cystathionine gamma-Lyase | 1 | 2017 | 35 | 0.040 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2018 | 109 | 0.040 |
Why?
| | Epithelium | 1 | 2018 | 315 | 0.040 |
Why?
| | Transplantation, Autologous | 1 | 2018 | 321 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2019 | 325 | 0.040 |
Why?
| | Equipment Safety | 1 | 2016 | 31 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 382 | 0.040 |
Why?
| | Thrombin | 1 | 2016 | 59 | 0.040 |
Why?
| | Risk | 1 | 2018 | 692 | 0.040 |
Why?
| | DNA Adducts | 1 | 2016 | 19 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2016 | 61 | 0.040 |
Why?
| | Renal Insufficiency | 1 | 2017 | 107 | 0.040 |
Why?
| | Arteriovenous Malformations | 1 | 2016 | 42 | 0.040 |
Why?
| | Swine | 1 | 2018 | 560 | 0.040 |
Why?
| | DNA Glycosylases | 1 | 2016 | 21 | 0.040 |
Why?
| | Deoxyguanosine | 1 | 2016 | 27 | 0.040 |
Why?
| | Prevalence | 1 | 2020 | 1233 | 0.040 |
Why?
| | Length of Stay | 1 | 2019 | 685 | 0.040 |
Why?
| | Hydrolysis | 1 | 2016 | 153 | 0.040 |
Why?
| | Atovaquone | 1 | 2015 | 4 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2018 | 175 | 0.040 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2015 | 5 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2001 | 615 | 0.040 |
Why?
| | Adolescent | 2 | 2020 | 8911 | 0.040 |
Why?
| | Phenylephrine | 1 | 2015 | 40 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 281 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2015 | 50 | 0.040 |
Why?
| | Isoproterenol | 1 | 2015 | 68 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2016 | 146 | 0.040 |
Why?
| | Respiration | 1 | 2017 | 240 | 0.040 |
Why?
| | Neuromuscular Junction Diseases | 1 | 2014 | 3 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2015 | 72 | 0.040 |
Why?
| | Contrast Media | 1 | 2020 | 1066 | 0.040 |
Why?
| | Pandemics | 1 | 2020 | 465 | 0.040 |
Why?
| | Equipment Design | 1 | 2016 | 413 | 0.040 |
Why?
| | Myofibroblasts | 1 | 2015 | 34 | 0.040 |
Why?
| | Sex Factors | 1 | 2018 | 1082 | 0.040 |
Why?
| | Cell Death | 1 | 2016 | 269 | 0.040 |
Why?
| | Lung Diseases | 1 | 2017 | 263 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2019 | 1786 | 0.040 |
Why?
| | Chicago | 1 | 2019 | 1416 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 107 | 0.040 |
Why?
| | KATP Channels | 1 | 2014 | 18 | 0.040 |
Why?
| | Radiography, Abdominal | 1 | 2014 | 65 | 0.040 |
Why?
| | Ultrasonography, Doppler | 1 | 2014 | 67 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2017 | 1195 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 31 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1025 | 0.040 |
Why?
| | Adenosine Triphosphatases | 1 | 2015 | 153 | 0.040 |
Why?
| | Carotid Body | 1 | 2017 | 223 | 0.030 |
Why?
| | Aortography | 1 | 2013 | 63 | 0.030 |
Why?
| | rho GTP-Binding Proteins | 1 | 2013 | 54 | 0.030 |
Why?
| | Calgranulin B | 1 | 2013 | 11 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2015 | 736 | 0.030 |
Why?
| | Fatty Acids | 1 | 2014 | 146 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2016 | 393 | 0.030 |
Why?
| | Tetrazolium Salts | 1 | 2012 | 12 | 0.030 |
Why?
| | Hypotension | 1 | 2013 | 74 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2082 | 0.030 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2013 | 79 | 0.030 |
Why?
| | NFATC Transcription Factors | 1 | 2012 | 28 | 0.030 |
Why?
| | Leucine | 1 | 2012 | 69 | 0.030 |
Why?
| | Body Weight | 1 | 2014 | 486 | 0.030 |
Why?
| | Histone Demethylases | 1 | 2012 | 25 | 0.030 |
Why?
| | Stroke | 1 | 2020 | 765 | 0.030 |
Why?
| | Zinc | 1 | 2013 | 90 | 0.030 |
Why?
| | Quality of Life | 1 | 2020 | 1277 | 0.030 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 978 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 73 | 0.030 |
Why?
| | Immunoglobulin E | 1 | 2012 | 142 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2013 | 99 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2012 | 117 | 0.030 |
Why?
| | Fibrosis | 1 | 2012 | 179 | 0.030 |
Why?
| | Thiazoles | 1 | 2012 | 130 | 0.030 |
Why?
| | Aorta, Thoracic | 1 | 2013 | 171 | 0.030 |
Why?
| | Eosinophils | 1 | 2012 | 191 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2017 | 671 | 0.030 |
Why?
| | Heart Diseases | 1 | 2014 | 310 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 405 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 282 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 1367 | 0.030 |
Why?
| | Retreatment | 1 | 2011 | 103 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2015 | 682 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2012 | 247 | 0.030 |
Why?
| | Body Mass Index | 1 | 2014 | 757 | 0.030 |
Why?
| | Rats, Mutant Strains | 1 | 2010 | 27 | 0.030 |
Why?
| | SOXD Transcription Factors | 1 | 2010 | 1 | 0.030 |
Why?
| | Connexins | 1 | 2012 | 193 | 0.030 |
Why?
| | Up-Regulation | 1 | 2013 | 705 | 0.030 |
Why?
| | Biomimetics | 1 | 2010 | 25 | 0.030 |
Why?
| | Butadienes | 1 | 2010 | 33 | 0.030 |
Why?
| | African Americans | 1 | 2019 | 1152 | 0.030 |
Why?
| | SOX9 Transcription Factor | 1 | 2010 | 20 | 0.030 |
Why?
| | Losartan | 1 | 2010 | 46 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1055 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2010 | 103 | 0.030 |
Why?
| | Cell Membrane | 1 | 2014 | 693 | 0.030 |
Why?
| | Renin | 1 | 2010 | 77 | 0.030 |
Why?
| | Aggrecans | 1 | 2010 | 47 | 0.030 |
Why?
| | Chondrocytes | 1 | 2010 | 61 | 0.030 |
Why?
| | Hypertrophy | 1 | 2009 | 64 | 0.030 |
Why?
| | Nitriles | 1 | 2010 | 88 | 0.030 |
Why?
| | Heterochromatin | 1 | 2009 | 23 | 0.030 |
Why?
| | Chromatin | 1 | 2012 | 329 | 0.030 |
Why?
| | Nuclear Envelope | 1 | 2009 | 37 | 0.030 |
Why?
| | Vitamins | 1 | 2010 | 72 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2012 | 266 | 0.030 |
Why?
| | Stress Fibers | 1 | 2009 | 24 | 0.030 |
Why?
| | Catalase | 1 | 2009 | 57 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2010 | 253 | 0.030 |
Why?
| | Diet | 1 | 2013 | 439 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 2010 | 162 | 0.030 |
Why?
| | Laminin | 1 | 2009 | 84 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2019 | 1403 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 2010 | 322 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 338 | 0.030 |
Why?
| | Binding Sites | 1 | 2012 | 1115 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 936 | 0.020 |
Why?
| | Adenoviridae | 1 | 2010 | 346 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1322 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2009 | 228 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2009 | 220 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 570 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2015 | 1187 | 0.020 |
Why?
| | Antioxidants | 1 | 2009 | 231 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 832 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 918 | 0.020 |
Why?
| | Indiana | 1 | 2006 | 11 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2010 | 671 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 560 | 0.020 |
Why?
| | Base Sequence | 1 | 2009 | 2422 | 0.020 |
Why?
| | Skin Diseases | 1 | 2006 | 162 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2006 | 259 | 0.020 |
Why?
| | Surgical Instruments | 1 | 2004 | 62 | 0.020 |
Why?
| | Apoptosis | 1 | 2010 | 1763 | 0.020 |
Why?
| | Carcinoma, Renal Cell | 1 | 2006 | 375 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 2006 | 558 | 0.010 |
Why?
|
|
Kim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|